Hyperbaric Oxygen and Scopolamine is a 1991 journal article by Bitterman and colleagues, published in Undersea Biomedical Research 18(3). Its subject brings together exposure to oxygen under increased pressure and scopolamine, a medicine with effects on the nervous system—an intersection relevant to medication use and human performance in diving environments.
Why consider scopolamine during hyperbaric exposure?
Scopolamine acts on muscarinic acetylcholine receptors, which are involved in signalling between nerves and organs. It is used in medicine for purposes including the prevention of motion sickness. Its effects can include drowsiness, blurred vision, dry mouth and changes in attention or memory; the response depends on the person, dose and circumstances.
Hyperbaric oxygen means breathing oxygen at a pressure greater than surface pressure. It is used in clinical treatment and studied in diving medicine, where pressure and the breathing gas both matter. Combining a drug exposure with hyperbaric conditions raises a practical question: could either influence the effects or risks associated with the other?
What does oxygen pressure change?
As ambient pressure rises, the partial pressure of oxygen in the breathing gas rises too. This increases oxygen availability to tissues, but breathing oxygen at elevated partial pressure can also affect the central nervous system. Central nervous system oxygen toxicity is a recognised concern in diving, though its onset and expression vary with exposure conditions and individual factors.
Possible signs of oxygen toxicity include visual or auditory disturbance, nausea, twitching and, in severe cases, seizure. These effects matter underwater because sudden impairment can threaten a diver’s ability to manage equipment, maintain a breathing supply and respond to an emergency. A medication that affects alertness or perception is therefore relevant to the broader assessment of performance and safety, even before any interaction is established.
Which concepts help frame the subject?
Work at the intersection of pharmacology and hyperbaric physiology needs to distinguish drug effects from pressure-related effects and from their possible interaction. The central concepts include:
- Hyperbaric oxygen: oxygen breathed at pressure above the surface environment, with effects shaped by oxygen partial pressure and exposure duration.
- Scopolamine: a medicine that blocks muscarinic receptors and can affect motion sickness, alertness and sensory function.
- Central nervous system oxygen toxicity: a potentially serious response to elevated oxygen exposure, with symptoms that can be difficult to manage underwater.
- Drug–environment interaction: the possibility that a medicine’s effects, a hyperbaric exposure, or both may change when they occur together.
- Human performance: attention, coordination and perception, all important to safe task completion during a dive or hyperbaric treatment.
These distinctions are useful because a symptom such as dizziness or impaired concentration can have more than one possible explanation. In diving medicine, recognising the exposure context is part of interpreting a symptom; it does not by itself establish its cause.
Why does this matter beyond one medicine?
Divers may face motion, workload, cold, stress and changing pressure while relying on clear perception and reliable coordination. A medicine that is acceptable in an ordinary setting may warrant a separate assessment when the person will be underwater or exposed to elevated pressure. The relevant question is not simply whether a drug is commonly used, but whether its effects fit the planned environment and task.
The same issue applies in clinical hyperbaric care, where treatment takes place under controlled pressure and clinicians must consider a patient’s condition and medication use. For both divers and patients, decisions depend on the indication, the person’s response, the exposure plan and the consequences of impairment. A diving-medicine or hyperbaric-medicine physician should assess individual cases.
How does this article fit into diving research?
Diving research often examines how environmental exposures interact with physiology, medication and task performance. Pressure-related gas effects, oxygen toxicity, narcosis, thermal strain and medication side effects are distinct topics, but real-world safety can depend on how several factors coincide. Research focused on a drug and a hyperbaric exposure belongs to this wider effort to understand those interactions.
The 1991 article’s title identifies scopolamine and hyperbaric oxygen as its subject. That pairing remains a useful frame for readers considering how pharmacology enters dive planning and treatment decisions: drug effects and exposure conditions need to be considered together, not in isolation.
Frequently asked questions
What is scopolamine?
What does hyperbaric oxygen mean?
Should a diver use scopolamine before diving?
Citation details
- Title: Hyperbaric Oxygen and Scopolamine
- Authors: Bitterman, N; Eilender, E; Melamed, Y
- Year: 1991
- Published in: Undersea Biomedical Research 18(3)
- Identifiers: PMID 1853467
- Record type: Journal article
- Repository record: Rubicon Research Repository, handle 123456789/2573
This page is an original summary written by the Rubicon editors from the publication’s bibliographic record. It does not reproduce the paper, its abstract or its data; consult the publication itself for its methods and findings.
Related reading on Rubicon
- The Physiology Behind Oxygen Toxicity in Deep Dives
- Understanding Oxygen Toxicity Risks and Prevention in Diving
- Oxygen Partial Pressure: Key to Dive Safety and Performance
- Myth Busting: Clarifying Oxygen Toxicity Limits in Diving
- Hyperbaric Oxygen for Diabetic Wounds: Research Summary
- Bleomycin and Hyperbaric Oxygen: Research Summary
- More on Dive Medicine
- Browse the Research Library